Structure-Based Optimization of Selective and Brain Penetrant CK1δ Inhibitors for the Treatment of Circadian Disruptions

  • ACS Med Chem Lett. 2024 Mar 7;15(4):486-492. doi: 10.1021/acsmedchemlett.3c00523.
Stefan McCarver  1 ,  Luke Hanna  1 ,  Andrew Samant  1 ,  Aaron A Thompson  1 ,  Mark Seierstad  1 ,  Arjun Saha  1 ,  Dongpei Wu  1 ,  Brian Lord  1 ,  Steven W Sutton  1 ,  Vishal Shah  1 ,  Cynthia M Milligan  1 ,  Michelle Wennerholm  1 ,  Jonathan Shelton  1 ,  Terry P Lebold  1 ,  Brock T Shireman  1
Affiliations
  • 1. Janssen Research and Development, San Diego, California 92121-1126, United States.
Abstract

Neuropsychiatric disorders such as major depressive disorders and Schizophrenia are often associated with disruptions to the normal 24 h sleep wake cycle. Casein Kinase 1 (CK1δ) is an integral part of the molecular machinery that regulates circadian rhythms. Starting from a cluster of bicyclic pyrazoles identified from a virtual screening effort, we utilized structure-based drug design to identify and reinforce a unique "hinge-flip" binding mode that provides a high degree of selectivity for CK1δ versus the kinome. Pharmacokinetics, brain exposure, and target engagement as measured by ex vivo autoradiography are described for advanced analogs.

Products